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Abstract
Background:  Telomerase is a ribonucleoprotein that synthesizes telomeres and plays an
important role in chromosomal stability and cellular immortalisation. Telomerase activity is
detectable in most human cancers but not in normal somatic cells. TGF beta (transforming growth
factor beta) is a member of a family of cytokines that are essential for cell survival and seems to be
down-regulated in human cancer. Recent in vitro work using human breast cancer cell lines has
suggested that TGF beta down-regulates the expression of hTERT (human telomerase reverse
transcriptase) : the catalytic subunit of telomerase. We have therefore hypothesised that
telomerase reactivation is associated with reduced immunohisto-chemical expression of TGF beta
type II receptor (RII) in human breast cancer.
Methods: TGF beta RII immunohistochemical expression was determined in 24 infiltrating breast
carcinomas with known telomerase activity (17 telomerase-positive and 7 telomerase-negative).
Immunohistochemical expression of TGF beta RII was determined by a breast pathologist who was
blinded to telomerase data.
Results: TGF beta RII was detected in all lesions. The percentage of stained cells ranged from 1–
100%. The difference in TGF beta RII expression between telomerase positive and negative
tumours was not statistically significant (p = 1.0).
Conclusion: The results of this pilot study suggest that there is no significant association between
telomerase reactivation and TGF-beta RII down-regulation in human breast cancer.
Background
Telomeres are highly specialised DNA structures at the
natural ends of chromosomes without which chromo-
somes become unstable [1–3]. In humans and other ver-
tebrates, the telomeric structures consist of thousands of
base pairs which are tandemly repeated. The repeat
sequences include AGGGTT for humans [4]. Progressive
shortening of telomeres occurs with each cell division,
which if continues without compensatory mechanisms,
would result in chromosomal instability and cellular
senescence in somatic cells [1–5]. Germline and malig-
nant cells compensate for the end replication problem by
Published: 06 July 2003
Cancer Cell International 2003, 3:9
Received: 30 March 2003
Accepted: 06 July 2003
This article is available from: http://www.cancerci.com/content/3/1/9
© 2003 Elkak et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/9
Page 2 of 5
(page number not for citation purposes)
expressing the enzyme telomerase which contains an RNA
complementary to telomeric AGGGTT repeats that per-
mits telomere synthesis onto chromosomal ends [4].
Using a polymerase chain reaction (PCR)-based assay
called the TRAP (telomeric repeat and amplification pro-
tocol) assay telomerase activity has been detected in most
malignant and germline cells but not in normal somatic
cells[4]. We previously reported telomerase activity in
72% of human breast carcinomas and in none of normal
or benign breast tissue specimens [6] Furthermore, we
observed a significant association between telomerase
activity and recognised prognostic indicators such as
nodal status, tumour size, Ki-67 expression and lym-
phovascular invasion [7,8].
TGF beta (transforming growth factor beta) is a member
of a family of dimeric polypeptide growth factors that
include bone morphogenic proteins and activins and is
essential for normal cell survival [9,10]. There are three
isoforms of TGF beta: TGF beta1, TGF beta2 and TGF
beta3 [9,10]. TGF beta binds to specific serine/threonine
kinase receptors which transmit intracellular signals
through Smad proteins [11]. The TGF beta receptor family
is divided into three groups: type I, type II and type III
receptors. Unlike type I and II receptors, type III receptor
does not have an intrinsic signalling function, but it seems
to regulate TGF beta access to the signalling receptors [12].
Type I and II receptors are transmembrane glycoproteins
which function as interdependent components of a heter-
opic complex: receptor I requires receptor II to bind TGF
beta, and receptor II requires receptor I to signal [13–16].
TGF beta has several biological effects depending upon
the type and state of the cell. In normal cells, TGF beta
arrests the cell in G1 phase, and there is an increasing
body of evidence that TGF beta suppresses carcinogenesis
[9,17]. Mutations in the gene for TGF beta, its receptors or
intracellular signalling molecules are important in the
pathogenesis of cancer [17]. Malignant cells, which both
increase the production of TGF beta and become resistant
to its growth inhibitory effects, become more invasive and
metastasize to distant organs [18].
Yang et al have recently reported that TGF beta can inhibit
telomerase activity by inhibiting hTERT transcription in
vitro [19]. The present study aims to examine the relation-
ship between telomerase and TGF beta RII in human
breast cancer.
Methods
The study was approved by the local ethics committee.
Using immunohistochemistry, TGF beta RII expression
was determined in 24 infiltrating breast carcinoma with
known telomerase activity by a pathologist who was
blinded to telomerase results.
TRAP assay for telomerase
Telomerase activity was determined by the PCR-based
TRAP assay as we described previously [18–20]. Figure 1
demonstrates typical telomerase positive and negative
results.
Immunohistochemistry
Staining
4 µm sections were cut from standard paraffin wax blocks
and mounted onto Superfost Plus slides. The sections
were placed in 60°C oven overnight and dewaxed in
xylene and placed in absolute alcohol for 2 minutes.
Endogenous peroxidase activity was blocked using meth-
anol and hydrogen peroxide. The sections were washed in
water. Heat mediated antigen retrieval was performed by
pressure cooking Tris EDTA Citrate Buffer (pH = 7.8) for
15 minutes. The sections were then placed in the pressure-
cooked Tris EDTA Citrate buffer and further pressure-
cooked for 8 minutes. The sections were then placed in
Tris buffer.
The rabbit affinity-purified polyclonal TGF beta RII anti-
body (L-21: sc-400, Santa Cruz Biotech) in a dilution of 1
in 300 was then applied and sections were incubated for
30 minutes, then washed in Tris buffer.
The second layer which consisted of peroxidase labelled
polymer conjugated to goat antirabbit immunoglobulins
(DAKO EnVision+ System Peroxidase, DAB, Code K4011)
was then added and incubated for 30 minutes. The slides
were then rinsed with Tris buffer. Liquid DAB+ substrate
chromogen solution (3,3'-diaminobenzidine chromogen
solution, DAKO EnVision+ System Peroxidase, DAB,
Code K4011) was then applied for 5–10 minutes after
which the slides were rinsed with water. The nuclei were
counterstained using haematoxylin. The slides were then
dehydrated, cleared and a coverslip was applied.
Scoring
The scoring system described by Gobbi et al [20] was used
for scoring. TGF beta – RII staining is mostly cytoplasmic
and was considered positive when the epithelial elements
stained for TGF beta RII. The endothelial cells of blood
vessels were used as internal positive control. The percent-
age of positive cells in breast cancers was assessed as 1 =
<25%, 2 = 25–75% and 3 = > 75%. The intensity of posi-
tive staining was grouped into weak = 1, moderate = 2 and
strong = 3 by comparing with the internal control. The
score for intensity was added to the score for percentage of
positive cells. Thus the minimum score was 2 and the
maximum score was 6.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/9
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Statistical analysis
We hypothesised that telomerase reactivation in human
breast cancer was associated with reduced immunohisto-
chemical expression of TGF beta RII. Fisher's exact test was
used to examine the association between telomerase activ-
ity and TGF beta RII expression. A p-value < 0.05 was con-
sidered significant.
Results
24 infiltrating breast carcinomas were included in this
study. The median patients' age was 60 years (range: 37–
87 years). Telomerase activity was detected in 17 (71%) of
24 tumours.
TGF beta RII was detected in all lesions. The percentage of
stained cells ranged from 1–100%. According to the per-
centage and intensity of staining, the tumours were
divided into two groups: group 1 (n = 12) with strong
staining in >75% of cells (score = 6) and group 2 (n = 12)
with weak to moderate staining in 1–75% of cells (score
<6). The results are summarised in table 1 and figure 2.
There was no significant association between telomerase
activity and down-regulation of TGF beta RII expression
(p = 1.0).
Discussion
This pilot study shows no significant association between
telomerase reactivation and TGF beta RII expression in
human breast cancer specimens. However, telomerase
negative lesions were more likely to have a strong staining
for TGF beta RII. Our initial hypothesis was that telomer-
ase reactivation in human breast cancer was associated
with reduced immunohisto-chemical expression of TGF
beta is based on the fact that both telomerase activation
[4–8] and genetic mutations related to TGF beta, its recep-
tors or intracellular signalling molecules [18,20] are asso-
ciated with carcinogenesis. The results of this study are not
consistent with the in vitro results reported by Yang et al
showing that autocrine TGF beta suppresses telomerase
activity and hTERT expression in human cancer cell lines
[19]. There are, however, two limitations in the present
study. Firstly, the sample size is small (n = 24). Secondly,
TRAP results in two breast tumours (TRAP +ve) and adjacent non-cancerous breast tissue (TRAP -ve) Figure 1
TRAP results in two breast tumours (TRAP +ve) and adjacent non-cancerous breast tissue (TRAP -ve). "Positive and negative" 
represent controls (squamous cell carcinoma of the head and neck and lysis buffer respectively). This figure shows the electro-
phoresis of PCR products on 10% polyacrylamide gel visualized by phospho-imager. Telomerase activity is indicated by the gen-
eration of a DNA ladder. The intensity of the bands correlates with telomerase activity.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/9
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TGF beta RII and telomerase expressions were measured
using two different methodologies. TGF beta RII expres-
sion was determined by IHC using a polyclonal antibody,
whereas telomerase expression was measured using a sen-
sitive PCR-based functional assay (TRAP). Furthermore,
IHC results depend upon the specificity of the antibody
used and this can be variable.
Moreover, immunohistochemical expression of a protein
does not always correlate with its functional activity.
Other possible explanations of this lack of association
may be the fact that we determined the expression of TGF-
beta RII rather than TGF beta itself. Because more than
one receptor, in addition to Smad, are involved in the
mechanism of action of TGF beta, therefore receptor II
expression may not be a true reflection of TGF beta activ-
ity. These contradicting results could also be explained on
the basis that carcinogenesis results from mutations in
any component of the TGF beta functional pathway
[9,17]. This suggests that the expression of TGF beta will
be totally different from the expression of its receptors in
terms of its relation to carcinogenesis. The study of Yang
et al [19] was conducted on cell lines under controlled
physiological conditions whereas this study was per-
formed on human breast cancer specimens where the can-
cer cells are influenced by numerous growth factors,
hormones and cytokines acting via endocrine and para-
crine pathways. We have recently demonstrated that
hTERT mRNA expression correlates with telomerase activ-
ity in human breast cancer [21], therefore the above
hypothesis can be examined by determining the mRNA
expression of hTERT, TGF beta, TGF beta RI and RII using
quantitative reverse transcriptase PCR (QRT-PCR)
methodology.
References
1. Morin GB: The human telomere terminal transferase enzyme
is a ribonucleoprotein that synthesises TTAGGG repeats Cell
1989, 59:521-9.
2. Counter CM, Avilion AA and LeFeuvre CE et al.: Telomere short-
ening associated with chromosome instability is arrested in
immortal cells which express telomerase activity  EMBO J
1992, 11:1921-1929.
3. Blackburn EH: Structure and formation of telomeres Nature
1991, 350:569-73.
4. Kim NW, Piatyszek MA and Prowse KR et al.: Specific association
of human telomerase activity with immortal cells and cancer
Science 1994, 266:2011-15.
5. Rhyu MS: Telomeres, Telomeres and immortality J Natl Cancer
Inst 1995, 87:884-94.
6. Mokbel K, Ghilchik M and Williams G et al.:  The association
between telomerase activity and hormone receptor status
and p53 expression in breast cancer Int J Surg Investig 2000,
1:509-16.
7. Mokbel K, Parris CN and Ghilchik M et al.:  The association
between telomerase activity, histopathological parameters
and Ki-67 expression in invasive breast cancer Am J Surg 1999,
178:69-72.
8. Mokbel K, Parris CN and Ghilchik M et al.: Telomerase activity
and lymphovascular invasion in breast cancer Eur J Surg Oncol
2000, 26:30-3.
9. Blobe GC, Schiemann WP and Lodish HF: Role of transforming
growth factor beta in human disease  N Engl J Med 2000,
342:1350-8.
10. Clark DA and Coker R: Transforming growth factor beta (TGF
beta) Int J Biochem Cell Biol 1998, 30:293-8.
11. Miyazono K: Positive and negative regulation of TGF beta
signalling J Cell Sci 2000, 113:1101-9.
12. Wang X-F, Lin HY and Ng-Eaton E et al.: Expression cloning and
characterization of the TGF beta type III receptor Cell 1991,
67:797-805.
13. Massague J: TGF beta signal transduction Ann Rev Biochem 1998,
67:753-791.
14. Lin HY, Wang X-F and Ng-Eaton E et al.: Expression cloning of the
TGF beta type II receptor, a functional transmembrane ser-
ine/ threonine kinase Cell 1992, 68:775-785.
15. Huse M, Chen Y-G and Massague J et al.: Crystal Structure of the
cytoplasmic domain of type I TGF beta receptor in complex
with FKBP 12 Cell 1999, 96:425-436.
Table 1: Telomerase activity and TGF beta RII expression (p = 1.0).
Parameter Telomerase Positive Telomerase Negative Total
TGF beta RII Strong Positive 8 (47%) 4 (57%) 12
TGF beta RII Moderate/Weak Positive 9 (53%) 3 (43%) 12
Total 17 7 24
Telomerase and TGF beta RII expression in human breast  cancer Figure 2
Telomerase and TGF beta RII expression in human breast 
cancer. The 'y' axis shows the percentage of positive samples.
0
10
20
30
40
50
60
TRAP+ TRAP-
TGF-B+
TGF-B-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/9
Page 5 of 5
(page number not for citation purposes)
16. Wrana JL, Attisano L and Carcamo J et al.:  TGF beta signals
through a heteromeic protein kinase receptor complex Cell
1992, 71:1003-1014.
17. Grady WM, Myeroff LL and Swinler SE et al.: Mutational inactiva-
tion of transforming growth factor beta receptor type II in
microsatellite stable colon cancers Cancer Res 1999, 59:320-4.
18. Hojo M, Morimoto T and Maluccio M et al.: Cyclosporine induces
cancer progression by a cell autonomous mechanism Nature
1999, 397:530-4.
19. Yang H, Kyo S and Takatura M et al.: Autocrine transforming
growth factor beta suppresses telomerase activity and tran-
scription of human telomerase reverse transcriptase in
human cancer cells Cell Growth Differ 2001, 12:119-27.
20. Gobbi H, Arteaga CL and Jensen RA et al.: Loss of expression of
transforming growth factor beta type II receptor correlates
with high tumour grade in human breast in-situ and invasive
carcinomas Histopathology 2000, 36:168-77.
21. Kirkpatrick KL, Clarke G, Ghilchik M, Newbold RF and Mokbel K:
Telomerase activity correlates with hTERT mRNA expres-
sion in human breast cancer Eur J Surg Oncol 2002.